



truscreen
a world without
cervical cancer

NZX/ASX Announcement

9 September 2021

Recording of Truscreen Group Limited ASM Virtual Meeting

The Annual Shareholder Meeting of Truscreen Group Limited (NZX:TRU) was held online on 7 September 2021 on Link Market Services virtual platform.

A recording is available online at:

<https://vimeo.com/599257567/d235b15307>

-ENDS-

For more information, visit www.truscreen.com or contact:

Tony Ho
Chairman
tonyho@truscreen.com

Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant.